Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¸ÞµðÄõð¹ÙÀ̽º > ¹ÙÀÌ¿ÀÀåºñ > ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå Àü¸Á(¡­2017³â) : ÀÓ»óÈ­Çа˻ç, À¯ÀüÀÚ °Ë»ç, Ç÷¾×°Ë»ç, Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¸é¿ªÈ­Çа˻ç, °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì»ý¹° ¹è¾ç °Ë»ç
Ä«Å×°í¸®
¸ÞµðÄõð¹ÙÀ̽º (4663)
³»½Ã°æ (161)
ºÐÀÚ¿µ»ó/Á¶¿µÁ¦ (28)
½ÉÇ÷°üÀåÄ¡ (336)
¾È°ú±â±â (102)
ÀÇ·á¿ë ¿µ»óÁø´ÜÀåÄ¡ (416)
ÀÇ·á¿ë ÀÏȸ¿ëǰ (77)
Á¤Çü¿Ü°ú (340)
â»ó°ü¸® (163)
ü¿ÜÁø´ÜÀåÄ¡(IVD) (520)
ÃÊÀ½ÆÄ (55)
Ä¡°ú±â±â (176)
Ä«Å×ÅÍ (239)
ÇÙÀÇ·á (76)
ÇコÄɾî IT (315)
ȯÀÚ¸ð´ÏÅ͸µ (390)
CT/MRI/X-ray (173)
½ÃÀ庸°í¼­

ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå Àü¸Á(¡­2017³â) : ÀÓ»óÈ­Çа˻ç, À¯ÀüÀÚ °Ë»ç, Ç÷¾×°Ë»ç, Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¸é¿ªÈ­Çа˻ç, °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì»ý¹° ¹è¾ç °Ë»ç

North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

¸®¼­Ä¡»ç GlobalData
¹ßÇàÀÏ 2012³â 01¿ù »óǰÄÚµå 229185
ÆäÀÌÁö Á¤º¸ Pages: 439
°¡°Ý
US $ 3,500 £Ü 4,170,200 PDF by E-mail (Single user license)
US $ 7,000 £Ü 8,340,500 PDF by E-mail (Site license)
US $ 10,500 £Ü 12,510,700 PDF by E-mail (Global license)


GlobalData ¿¡¼­ 2012³â 01¿ù ¿¡ ¹ßÇàÇÑ ¡¸ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå Àü¸Á(¡­2017³â) : ÀÓ»óÈ­Çа˻ç, À¯ÀüÀÚ °Ë»ç, Ç÷¾×°Ë»ç, Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¸é¿ªÈ­Çа˻ç, °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì»ý¹° ¹è¾ç °Ë»ç¡¹ º¸°í¼­´Â Pages: 439·Î ±¸¼ºµÇ¾î, US $3,500 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü(In Vitro Diagnostics) ½ÃÀå¿¡ ´ëÇØ ½ÃÀå Àüü ¹× ±¹°¡º°·Î ºÐ¼®Çϰí, °¢±¹ÀÇ ÃѸÅÃâ ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ, ±â¾÷ ¹× À¯Åë Á¡À¯À² µ¥ÀÌÅÍ, ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°º° ºÐ¼®, ü¿ÜÁø´Ü ½ÃÀå¿¡ °üÇÑ ±ÔÁ¦, À繫 °Å·¡ »óȲ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

1. ¸ñÂ÷

  • 1.1 Ç¥
  • 1.2 ±×¸²

2. ¼­·Ð

  • 2.1 º» º¸°í¼­¿¡ ´ëÇØ

3. ü¿ÜÁø´Ü : ºÏ¹Ì

  • 3.1 ü¿ÜÁø´Ü ´Ù±¹°£ ºñ±³, USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • 3.2 ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • 3.3 ü¿ÜÁø´Ü, ºÏ¹Ì, ±â¾÷ Á¡À¯À²

4. ü¿ÜÁø´Ü : ij³ª´Ù

  • 4.1 ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • 4.2 ü¿ÜÁø´Ü, ij³ª´Ù, À¯Åë Á¡À¯À²
  • 4.3 ü¿ÜÁø´Ü, ij³ª´Ù, ±â¾÷ Á¡À¯À²

5. ü¿ÜÁø´Ü : ¹Ì±¹

  • 5.1 ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • 5.2 ü¿ÜÁø´Ü, ¹Ì±¹ À¯Åë Á¡À¯À²
  • 5.3 ü¿ÜÁø´Ü, ¹Ì±¹, ±â¾÷ Á¡À¯À²

6. ÁÖ¿ä ±â¾÷ °³¿ä : ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå

  • 6.1 Abbott Laboratories
  • 6.2 Siemens Healthcare
  • 6.3 F. Hoffmann-La Roche Ltd.
  • 6.4 Beckman Coulter, Inc.
  • 6.5 Ortho-Clinical Diagnostics Inc.
  • 6.6 bioMerieux S.A.
  • 6.7 Becton, Dickinson and Company
  • 6.8 Bio-Rad Laboratories, Inc.
  • 6.9 Alere Inc.
  • 6.10 Sysmex Corporation
  • 6.11 Qiagen N.V.
  • 6.12 Gen-Probe Incorporated
  • 6.13 DiaSorin S.p.A
  • 6.14 Thermo Fisher Scientific Inc.
  • 6.15 Immucor, Inc.
  • 6.16 Hologic, Inc.
  • 6.17 Phadia AB
  • 6.18 Cepheid
  • 6.19 Grifols, S.A.
  • 6.20 Life Technologies Corporation
  • 6.21 PerkinElmer, Inc.
  • 6.22 HORIBA, Ltd.
  • 6.23 Biomedica Diagnostics Inc.
  • 6.24 OraSure Technologies, Inc.

7. ü¿ÜÁø´Ü ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°

  • 7.1 ÀÓ»óÈ­ÇÐ°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.2 ¸é¿ªÈ­ÇÐ°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.3 Ç÷¾×°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.4 °¨¿° ¹× ¸é¿ª °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.5 ¹Ì»ý¹° ¹è¾ç °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.6 Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • 7.7 À¯ÀüÀÚ °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°

8. À繫 °Å·¡ Àü¸Á

  • 8.1 ÇÕº´
  • 8.2 Àμö
  • 8.3 Á¦ÈÞ

9. Ãֽе¿Çâ

  • 9.1 Àü·« ¹× »ç¾÷ °èȹ
  • 9.2 Á¦Ç° Á¤º¸
  • 9.3 ¹ýÀû ÇàÀ§ ¹× ±ÔÁ¦
  • 9.4 Á¤ºÎ ¹× °øÀÍ °ü·Ã

10. ºÎ·Ï

  • 10.1 Á¶»ç ´ë»ó ½ÃÀå Á¤ÀÇ
  • 10.2 Á¶»ç ¹æ¹ý
  • 10.3 2Â÷ Á¶»ç
  • 10.4 1Â÷ Á¶»ç
  • 10.5 µ¥ÀÌÅÍÀÇ ¸ðµ¨È­
  • 10.6 ¿¹Ãø
  • 10.7 Àü¹®°¡ÀÇ ÀÎÁõ
  • 10.8 GlobalDataÀÇ ÄÁ¼³ÆÃ ¼­ºñ½º
  • 10.9 ÅëÈ­ ȯ»ê
  • 10.10 ¹®ÀÇ
  • 10.11 ¸éÃ¥»çÇ×

Ç¥

  • Ç¥ 1 : ü¿ÜÁø´Ü, ´Ù±¹°£ ºñ±³, USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • Ç¥ 2 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • Ç¥ 3: ü¿ÜÁø´Ü, ºÏ¹Ì, Ä«Å×°í¸®°£ ºÐ¼®, ½ÇÀû ¹× ¿¹Ãø
  • Ç¥ 4 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • Ç¥ 5 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • Ç¥ 6 : ü¿ÜÁø´Ü, ºÏ¹Ì, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 7 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • Ç¥ 8 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • Ç¥ 9 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • Ç¥ 10 : ÀÓ»óÈ­Çа˻ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 11 : À¯ÀüÀÚ °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 12 : Ç÷¾×°Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 13 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 14 : ¸é¿ªÈ­Çа˻ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 15 : °¨¿° ¹× ¸é¿ª °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 16 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 17 : ü¿ÜÁø´Ü, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 18 : ÀÓ»óÈ­Çа˻ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 19 : À¯ÀüÀÚ °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 20 : Ç÷¾×°Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 21 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 22 : ¸é¿ªÈ­Çа˻ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 23 : °¨¿° ¹× ¸é¿ª °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 24 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ij³ª´Ù, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 25 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • Ç¥ 26 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • Ç¥ 27 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • Ç¥ 28 : ÀÓ»óÈ­Çа˻ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 29 : À¯ÀüÀÚ °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 30 : Ç÷¾×°Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 31 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 32 : ¸é¿ªÈ­Çа˻ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 33 : °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 34 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ À¯Åë Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 35 : ü¿ÜÁø´Ü, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 36 : ÀÓ»óÈ­Çа˻ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 37 : À¯ÀüÀÚ °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 38 : Ç÷¾×°Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 39 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 40 : ¸é¿ªÈ­Çа˻ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 41 : °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 42 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ¹Ì±¹, ¸ÅÃ⺰ ±â¾÷ Á¡À¯À²($m), USD ½Ç¾× ±âÁØ
  • Ç¥ 43: ÀÓ»óÈ­ÇÐ°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 44: ¸é¿ªÈ­ÇÐ°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 45: Ç÷¾×°Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 46: °¨¿° ¹× ¸é¿ª °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 47: ¹Ì»ý¹° ¹è¾ç °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 48: Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 49: À¯ÀüÀÚ °Ë»ç ½ÃÀå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°
  • Ç¥ 50-173: ü¿ÜÁø´Ü ½ÃÀå, ºÏ¹Ì, °Å·¡ ³»¿ë »ó¼¼
  • Ç¥ 174: ´Þ·¯ ´ëºñ ÇöÁöÅëÈ­, ºÏ¹Ì, Æò±Õ ȯÀ²

±×¸²

  • ±×¸² 1 : ü¿ÜÁø´Ü, ´Ù±¹°£ ºñ±³, USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • ±×¸² 2 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • ±×¸² 3: ü¿ÜÁø´Ü, ºÏ¹Ì, Ä«Å×°í¸®°£ ºÐ¼®, ½ÇÀû ¹× ¿¹Ãø
  • ±×¸² 4 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • ±×¸² 5 : ü¿ÜÁø´Ü, ºÏ¹Ì, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • ±×¸² 6 : ü¿ÜÁø´Ü, ºÏ¹Ì, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 7 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • ±×¸² 8 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • ±×¸² 9 : ü¿ÜÁø´Ü, ij³ª´Ù, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • ±×¸² 10 : ü¿ÜÁø´Ü, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 11 : ÀÓ»óÈ­Çа˻ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 12 : À¯ÀüÀÚ °Ë»ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 13 : Ç÷¾×°Ë»ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 14 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 15 : ¸é¿ªÈ­Çа˻ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 16 : °¨¿° ¹× ¸é¿ª °Ë»ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 17 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ij³ª´Ù, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 18 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû ¹× ¿¹Ãø
  • ±×¸² 19 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ½ÇÀû
  • ±×¸² 20 : ü¿ÜÁø´Ü, ¹Ì±¹, Àüü ¸ÅÃâ($m), USD ½Ç¾× ±âÁØ, ¿¹Ãø
  • ±×¸² 21 : ü¿ÜÁø´Ü, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 22 : ÀÓ»óÈ­Çа˻ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 23 : À¯ÀüÀÚ °Ë»ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 24 : Ç÷¾×°Ë»ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 25 : Á¶Á÷ ¹× ¼¼Æ÷ °Ë»ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 26 : ¸é¿ªÈ­Çа˻ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 27 : °¨¿° ¹× ¸é¿ª °Ë»ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 28 : ¹Ì»ý¹° ¹è¾ç °Ë»ç, ¹Ì±¹, ±â¾÷ Á¡À¯À²(%)
  • ±×¸² 29 : Abbott Laboratories, ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå
  • ±×¸² 30 : Siemens Healthcare, ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå
  • ±×¸² 31 : F. Hoffmann-La Roche Ltd., ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå
  • ±×¸² 32 : Beckman Coulter, Inc., ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå
  • ±×¸² 33 : Ortho-Clinical Diagnostics Inc., ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå
  • ±×¸² 34 : bioMerieux S.A., ±â¾÷ Á¡À¯À²(%), ºÏ¹ÌÀÇ Ã¼¿ÜÁø´Ü ½ÃÀå

LSH
Back to Top